CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) has been assigned a consensus recommendation of “Buy” from the twenty ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $117.27.
Several equities analysts have recently issued reports on the company. The Goldman Sachs Group reduced their target price on CRISPR Therapeutics from $52.00 to $46.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 24th. BMO Capital Markets assumed coverage on CRISPR Therapeutics in a research note on Thursday. They set an “outperform” rating on the stock. Stifel Nicolaus boosted their target price on CRISPR Therapeutics from $52.00 to $57.00 in a research note on Monday. Royal Bank of Canada dropped their price target on CRISPR Therapeutics from $95.00 to $85.00 in a research report on Tuesday, May 10th. Finally, Credit Suisse Group started coverage on CRISPR Therapeutics in a research report on Thursday, April 28th. They set a “neutral” rating and a $78.00 price target on the stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. IMA Wealth Inc. increased its position in CRISPR Therapeutics by 13.5% in the first quarter. IMA Wealth Inc. now owns 27,979 shares of the company’s stock worth $1,756,000 after buying an additional 3,327 shares in the last quarter. Verition Fund Management LLC purchased a new stake in CRISPR Therapeutics in the first quarter worth about $252,000. Advisory Services Network LLC increased its position in CRISPR Therapeutics by 8.7% in the first quarter. Advisory Services Network LLC now owns 13,420 shares of the company’s stock worth $842,000 after buying an additional 1,069 shares in the last quarter. Capital International Sarl increased its position in CRISPR Therapeutics by 20.0% in the first quarter. Capital International Sarl now owns 24,189 shares of the company’s stock worth $1,518,000 after buying an additional 4,027 shares in the last quarter. Finally, Capital International Investors grew its position in shares of CRISPR Therapeutics by 0.3% during the first quarter. Capital International Investors now owns 3,602,152 shares of the company’s stock worth $226,107,000 after purchasing an additional 10,992 shares in the last quarter. Institutional investors and hedge funds own 56.12% of the company’s stock.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.38). The company had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.45 million. CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. CRISPR Therapeutics’s revenue for the quarter was up 74.4% on a year-over-year basis. During the same period last year, the firm earned ($1.51) earnings per share. On average, research analysts anticipate that CRISPR Therapeutics will post -8.97 EPS for the current fiscal year.
About CRISPR Therapeutics (Get Rating)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Dividend Stocks and Your Roth IRA
- The Analysts Upgrade… Retail Stocks?
- The Q2 Earnings Season Could Be A Bloodbath
- Commercial Metals Company Is Ready To Rebound
- The Institutions Turn The Tide For Jabil
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.